Previous 10 | Next 10 |
Penny Stocks Making Fresh Highs But Will They Leave Investors In The Dust? Investing in penny stocks can often prove to be one of the most rewarding especially when finding the best penny stocks to buy . Millions of people have made fortunes by investing in these cheap stocks. While it is t...
Intra-Cellular Therapies (NASDAQ: ITCI ) +89% after Caplyta approved by FDA. More news on: Intra-Cellular Therapies, Inc., Cincinnati Bell Inc., Seadrill Limited, Stocks on the move, Read more ...
AMES, Iowa, Dec. 20, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO® , or Zaire Ebola virus vaccine V920 (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck (NYS...
AMES, Iowa, Dec. 16, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink” or the “Company”) today publicly announced its rejection of the unsolicited acquisition proposal received on November 5, 2019 from Evercel, Inc. (“Everc...
NEW YORK, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Evercel, Inc. (“Evercel”) (OTC: EVRC) has made an offer to acquire NewLink Genetics Corporation ("NewLink") (NASDAQ: NLNK). Daniel Allen, Chief Executive Officer of Evercel, announced on November 25, 2019 Evercel has made ...
AMES, Iowa, Nov. 12, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11 th , the European Commission (EC) granted a conditional marketing authorization to ERVEBO®, investigational V920 Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP...
NewLink Genetics Corporation (NLNK) Q3 2019 Earnings Conference Call November 06, 2019 8:30 AM ET Company Participants Lisa Miller - Director, Investor Relations Carl Langren - Chief Financial Officer Eugene Kennedy - Chief Medical Officer Conference Call Participants Pres...
NewLink Genetics (NASDAQ: NLNK ): Q3 Non-GAAP EPS of -$0.39. Revenue of $0.25M (+108.3% Y/Y) Press Release More news on: NewLink Genetics Corporation, Earnings news and commentary, Healthcare stocks news, ,
AMES, Iowa, Nov. 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on corporate activities. “We are excited about the proposed merger with Lumos Pharma...
AMES, Iowa, Oct. 30, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its third quarter 2019 conference call and webcast at 8:30 AM ET on Wednesday, November 6, 2019, to discuss its third quarter financial results and provide an updat...
News, Short Squeeze, Breakout and More Instantly...
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock PR Newswire NEW ORLEANS ...
AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23...
- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash ...